99-7746. Medical Devices; Exemptions From Premarket Notification; Class II Devices  

  • [Federal Register Volume 64, Number 59 (Monday, March 29, 1999)]
    [Rules and Regulations]
    [Pages 14830-14831]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-7746]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    21 CFR Part 874
    
    [Docket No. 98P-0833]
    
    
    Medical Devices; Exemptions From Premarket Notification; Class II 
    Devices
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Final rule.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is publishing an order 
    granting a petition requesting exemption from the premarket 
    notification requirements for audiometers with certain limitations. FDA 
    is publishing this order in accordance with procedures established by 
    the Food and Drug Administration Modernization Act of 1997 (FDAMA).
    
    EFFECTIVE DATE: March 29, 1999.
    
    FOR FURTHER INFORMATION CONTACT: Heather S. Rosecrans, Center for 
    Devices and Radiological Health (HFZ-404), Food and Drug 
    Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-
    1190.
    
    SUPPLEMENTARY INFORMATION:
    
    I. Statutory Background
    
         Under section 513 of the Federal Food, Drug, and Cosmetic Act (the 
    act) (21 U.S.C. 360c), FDA must classify devices into one of three 
    regulatory classes: Class I, class II, or class III. FDA classification 
    of a device is determined by the amount of regulation necessary to 
    provide a reasonable assurance of safety and effectiveness. Under the 
    Medical Device Amendments of 1976 (the 1976 amendments (Pub. L. 94-
    295)), as amended by the Safe Medical Devices Act of 1990 (the SMDA) 
    (Pub. L. 101-629)), devices are to be classified into class I (general 
    controls) if there is information showing that the general controls of 
    the act are sufficient to ensure safety and effectiveness; into class 
    II (special controls), if general controls, by themselves, are 
    insufficient to provide reasonable assurance of safety and 
    effectiveness, but there is sufficient information to establish special 
    controls to provide such assurance; and into class III (premarket 
    approval), if there is insufficient information to support classifying 
    a device into class I or class II and the device is a life-sustaining 
    or life-supporting device or is for a use that is of substantial 
    importance in preventing impairment of human health, or presents a 
    potential unreasonable risk of illness or injury.
         Most generic types of devices that were on the market before the 
    date of the 1976 amendments (May 28, 1976) (generally referred to as 
    preamendments devices) have been classified by FDA under the procedures 
    set forth in section 513(c) and (d) of the act through the issuance of 
    classification regulations into one of these three regulatory classes. 
    Devices introduced into interstate commerce for the first time on or 
    after May 28, 1976 (generally referred to as postamendments devices) 
    are classified through the premarket notification process under section 
    510(k) of the act (21 U.S.C. 360(k)). Section 510(k) of the act and the 
    implementing regulations, 21 CFR part 807, require persons who intend 
    to market a new device to submit a premarket notification report 
    (510(k)) containing information that allows FDA to determine whether 
    the new device is ``substantially equivalent'' within the meaning of 
    section 513(i) of the act to a legally marketed device that does not 
    require premarket approval.
         On November 21, 1997, the President signed into law FDAMA (Pub. L. 
    105-115). Section 206 of FDAMA, in part, added a new section 510(m) to 
    the act. Section 510(m)(1) of the act requires FDA, within 60 days 
    after enactment of FDAMA, to publish in the Federal Register a list for 
    each type of class II device that does not require a report under 
    section 510(k) of the act to provide reasonable assurance of safety and 
    effectiveness. Section 510(m) of the act further provides that a 510(k) 
    will no longer be required for these devices upon the date of 
    publication of the list in the Federal Register. FDA published that 
    list in the Federal Register of January 21, 1998 (63 FR 3142).
         Section 510(m)(2) of the act provides that 1 day after date of 
    publication of the list under section 510(m)(1) of the act, FDA may 
    exempt a device on its own initiative or upon petition of an interested 
    person, if FDA determines that a 510(k) is not necessary to provide 
    reasonable assurance of the safety and effectiveness of the device. 
    This section requires FDA to publish in the Federal Register a notice 
    of intent to exempt a device, or of the petition, and to provide a 30-
    day comment period. Within 120 days of publication of this document, 
    FDA must publish in the Federal Register its final determination 
    regarding the exemption of the device that was the subject of the 
    notice. If FDA fails to respond to a petition under this section within 
    180 days of receiving it, the petition shall be deemed granted.
    
    [[Page 14831]]
    
     II. Criteria for Exemption
    
         There are a number of factors FDA may consider to determine 
    whether a 510(k) is necessary to provide reasonable assurance of the 
    safety and effectiveness of a class II device. These factors are 
    discussed in the guidance the agency issued on February 19, 1998, 
    entitled ``Procedures for Class II Device Exemptions from Premarket 
    Notification, Guidance for Industry and CDRH Staff.'' That guidance can 
    be obtained through the World Wide Web on the CDRH home page at 
    ``http://www.fda.gov/cdrh'' or by facsimile through CDRH Facts-on-
    Demand at 1-800-899-0381 or 301-827-0111. Specify ``159'' when prompted 
    for the document shelf number.
    
     III. Petitions
    
         FDA has received a petition requesting an exemption from premarket 
    notification for the audiometer (21 CFR 874.1050).
         In the Federal Register of November 18, 1998 (63 FR 64091), FDA 
    published a notice announcing that this petition had been received and 
    providing an opportunity for interested persons to submit comments on 
    the petition by December 18, 1998. FDA received one comment that 
    supported the proposal. FDA has reviewed the petition and has 
    determined that this device meets the criteria for exemption described 
    previously, provided that certain conditions are met. The petitioner 
    stated that manufacturers of audiometers voluntarily comply with a 
    consensus standard for audiometers, American National Standards 
    Institute (ANSI), S3.6 (R1996)\1\. FDA believes that compliance with 
    this standard obviates the need for premarket notifications and is, 
    therefore, issuing this order exempting these devices from the 
    requirements of premarket notification, provided that they are in 
    compliance with this standard, and is codifying this order in the Code 
    of Federal Regulations. Audiometers that do not comply with this 
    standard are not exempt from the premarket notification requirements. 
    FDA also notes that otoacoustic emissions test devices are not exempt 
    from the the premarket notification requirements. Because the 
    otoacoustic emissions test device is not a type of audiometer, it is 
    not completely covered by the ANSI standard and, therefore, is not 
    subject to the exemption.
    ---------------------------------------------------------------------------
    
        \1\ The standard is available from the American National 
    Standards Institute, Standards Secretariat, Acoustical Society of 
    America, 120 Wall St., 32d Floor, New York, NY 10005-3993.
    ---------------------------------------------------------------------------
    
     IV. Environmental Impact
    
         The agency has determined under 21 CFR 25.30(h) that this action 
    is of a type that does not individually or cumulatively have a 
    significant effect on the human environment. Therefore, neither an 
    environmental assessment nor an environmental impact statement is 
    required.
    
     V. Analysis of Impacts
    
         FDA has examined the impacts of the final rule under Executive 
    Order 12866 and the Regulatory Flexibility Act (5 U.S.C. 601-612), as 
    amended by subtitle D of the Small Business Regulatory Fairness Act of 
    1996 (Pub. L. 104-121) and the Unfunded Mandates Reform Act of 1995 
    (Pub. L. 104-4). Executive Order 12866 directs agencies to assess all 
    costs and benefits of available regulatory alternatives and, when 
    regulation is necessary, to select regulatory approaches that maximize 
    net benefits (including potential economic, environmental, public 
    health and safety, and other advantages; distributive impacts; and 
    equity). The agency believes that this final rule is consistent with 
    the regulatory philosophy and principles identified in the Executive 
    Order. In addition, the final rule is not a significant regulatory 
    action as defined by the Executive Order and so is not subject to 
    review under the Executive Order.
         If a rule has a significant economic impact on a substantial 
    number of small entities, the Regulatory Flexibility Act requires 
    agencies to analyze regulatory options that would minimize any 
    significant impact of a rule on small entities. Because this rule will 
    relieve a burden and simplify the marketing of these devices, the 
    agency certifies that the final rule will not have a significant 
    economic impact on a substantial number of small entities. Therefore, 
    under the Regulatory Flexibility Act, no further analysis is required.
    
     VI. Paperwork Reduction Act of 1995
    
         FDA concludes that this final rule contains no collections of 
    information. Therefore, clearance by the Office of Management and 
    Budget under the Paperwork Reduction Act of 1995 is not required.
    
     List of Subjects in 21 CFR Part 874
    
        Medical devices.
         Therefore, under the Federal Food, Drug, and Cosmetic Act and 
    under authority delegated to the Commissioner of Food and Drugs, 21 CFR 
    part 874 is amended as follows:
    
    PART 874--EAR, NOSE, AND THROAT DEVICES
    
         1. The authority citation for 21 CFR part 874 continues to read as 
    follows:
    
         Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 371.
    
         2. Section 874.1050 is amended by revising paragraph (b) to read 
    as follows:
    
    
    Sec. 874.1050   Audiometer.
    
    * * * * *
         (b) Classification. Class II. Except for the otoacoustic emission 
    device, the device is exempt from the premarket notification procedures 
    in subpart E of part 807 of this chapter, if it is in compliance with 
    American National Standard Institute S3.6-1996, ``Specification for 
    Audiometers,'' and subject to the limitations in Sec. 874.9.
    
        Dated: March 24, 1999.
     William K. Hubbard,
     Acting Deputy Commissioner for Policy.
    [FR Doc. 99-7746 Filed 3-26-99; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Effective Date:
3/29/1999
Published:
03/29/1999
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
99-7746
Dates:
March 29, 1999.
Pages:
14830-14831 (2 pages)
Docket Numbers:
Docket No. 98P-0833
PDF File:
99-7746.pdf
CFR: (1)
21 CFR 874.1050